Novel RNA Vaccine Shows Promise for Treating Multiple Allergies

An international research team led by the Technical University of Denmark (DTU) has developed an RNA-based vaccine that could revolutionize allergy treatment. The vaccine, created in collaboration with the Complutense University of Madrid (UCM), IBIMA-Plataforma BIONAND (Málaga), and hospitals in Barcelona, has demonstrated the ability to neutralize the effects of both food and pollen allergens in animal models.

The Challenge of Multiple Allergies

Currently, managing multiple allergies, particularly in individuals polysensitized to numerous homologous allergens, presents a significant challenge. Avoiding all allergenic sources is often impractical and can lead to serious reactions if accidental ingestion occurs. Existing immunotherapy, while potentially curative, is a lengthy process with no guarantee of complete protection and carries the risk of adverse reactions, leading to high dropout rates.

A Novel Immunotherapy Platform

Researchers aimed to create a therapy capable of simultaneously targeting multiple allergies safely and effectively. Their approach involved designing an artificial protein – a “consensus allergen” – representing the average structural characteristics of a family of allergens responsible for cross-reactivity. This molecule, while not naturally occurring, contains key immunogenic elements common to relevant allergens, inducing an immune response against multiple sources with a single treatment. The characterization of this allergen was conducted at the Faculty of Chemical Sciences of the UCM .

Leveraging mRNA Technology

The team utilized messenger RNA (mRNA) technology, similar to that employed in COVID-19 vaccines, to deliver the allergen. In this approach, the RNA acts as a carrier, prompting the body’s cells to synthesize the allergen in a controlled manner. This triggers an immune response against the allergy-causing molecules, blocking their ability to cause a reaction and instead fostering a protective immune response.

Promising Results in Animal Models

Experiments in animal models showed the immunotherapy induced antibodies capable of recognizing and blocking allergens from various food sources and pollens, even exceeding the protection offered by traditional immunotherapy with individual natural allergens. Importantly, the treatment was safe in the studied models, with no adverse reactions observed during immunization.

Even in a severe allergy model, treated animals exhibited an improved immunological profile, suggesting that optimizing the formulation and administration route could lead to an effective therapeutic solution for patients with multiple allergies.

International Collaboration and Future Directions

This research represents a new avenue for developing broader, safer, and customizable immunotherapies. It highlights the importance of international collaboration, with the Complutense University of Madrid playing a key role in cutting-edge biomedical research. The approach could potentially lay the groundwork for future therapies targeting other complex allergies, impacting the over seven million people in Europe affected by these conditions.

Understanding Allergens

Allergies arise from an overreaction of the immune system to generally harmless proteins, known as allergens. Symptoms can range from mild to severe, potentially leading to anaphylactic shock. Allergens often share structural similarities across different plant species, meaning someone sensitized to one food may experience allergies to others or to pollens through homologous allergens. A prime example is the non-specific lipid transfer protein (nsLTP) allergic syndrome, a common food allergy in southern Europe, with peach allergens serving as a key reference point for this protein family.